Nektar Therapeutics (NKTR) Tops Q3 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq retreat from record highs as yields and oil climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Nektar Therapeutics (NKTR) PT Raised to $20 at Oppenheimer
November 7, 2019 10:24 AM ESTOppenheimer analyst Jay Olson raised the price target on Nektar Therapeutics (NASDAQ: NKTR) to $20.00 (from $18.00) while maintaining a Perform rating.
The analyst commented, "Nektar reported 3Q19 financial results, revised 2019 guidance, and provided pipeline updates including multiple catalysts. While NKTR has several promising... More



